Medicus Pharma (MDCX) announces that it has submitted an FDA Commissioner’s national priority voucher, CNPV, application on behalf of Skinject, SKNJCT-003, evaluating Doxorubicin Microneedle Array, D-MNA, to non-invasively treat basal cell carcinoma, BCC, of the skin. The submission includes a complete Statement of Interest outlining SkinJect’s alignment with FDA national priorities in cancer care access, affordability, and rare-disease needs.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDCX:
- Medicus Pharma Reports Q3 Loss Amid Strategic Growth
- Medicus Pharma Expands Phase 2 BCC Clinical Study to the UK
- Medicus Pharma receives full UK regulatory approvals to expand Phase 2 study
- Medicus Pharma Ltd’s Strategic Collaboration and Promising Phase 2 Results Justify Buy Rating
- Medicus Pharma Collaborates with Gorlin Syndrome Alliance for SKINJECT™ Access